UNSPSC 51141518: Levetiracetam

This classification denotes a neuroprotective agent and anticonvulsant agent with the molecular formula C8H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 44YRR34555, chemically known as 1-pyrrolidineacetamide, alpha-ethyl-2-oxo-, (s)- but generally known as levetiracetam, which bears US NIH Compound Identifier 59708. European Medicines Agency schedules Levetiracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08459MIG.

UNSPSC 51141518 Levetiracetam (Commodity) shows minimal recent alignment with state and local procurement activity. The three most recent opportunities tagged to this code involve naloxone procurement, direct-to-manufacturer pharmacy prescription programs, and generic multi-source pharmaceuticals and over-the-counter products—none of which directly concern levetiracetam, an anti-seizure medication. The code nominally identifies a single pharmaceutical product, yet the recent solicitations reveal that state and local buyers use broader pharmaceutical procurement frameworks that aggregate multiple drugs across therapeutic categories, wholesalers, and pricing models rather than procuring individual pharmaceutical entities by NDC or active ingredient.

The issuing bodies in recent activity include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota and Oregon state and local facilities). Geographic distribution spans Florida, Texas, Minnesota, and Oregon, though the cooperative purchasing vehicle suggests participation from additional jurisdictions. Representative opportunities include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023, though the posting date of June 30, 2026 suggests a data error in the source), Texas HHS Commission's RFI on direct-to-manufacturer prescriptions (due April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026). The mismatch between the code's nominal scope and the actual work being solicited indicates that levetiracetam as a discrete commodity does not currently generate standalone state and local procurement activity; instead, buyers source it through broader pharmaceutical supply agreements managed by state procurement offices and cooperative purchasing alliances.